Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
136.12(c) 140.79(c) 140.68(c) 142.04(c) 142.4(c) Last
5 120 140 11 717 348 6 827 734 9 181 291 5 620 340 Volume
-0.23% +3.43% -0.08% +0.97% +0.25% Change
More quotes
Financials ($)
Sales 2017 76 267 M
EBIT 2017 23 526 M
Net income 2017 15 953 M
Debt 2017 16 641 M
Yield 2017 2,35%
Sales 2018 80 546 M
EBIT 2018 25 820 M
Net income 2018 19 263 M
Debt 2018 7 384 M
Yield 2018 2,52%
P/E ratio 2017 24,46
P/E ratio 2018 19,91
EV / Sales2017 5,23x
EV / Sales2018 4,84x
Capitalization 382 B
More Financials
Company
Johnson & Johnson is an investment holding company with interests in health care products.It engages in research and development, manufacture and sale of personal care hygienic products, pharmaceuticals and surgical equipment.The company operates through the following business segments: Consumer,... 
Sector
Pharmaceuticals
Calendar
01/23 | 12:40pmEarnings Release
More about the company
Surperformance© ratings of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
Latest news on JOHNSON & JOHNSON
05:37a JOHNSON & JOHNSON : California judge tosses $417 mln talc cancer verdict against..
04:22a JOHNSON & JOHNSON : Judge tosses $417M award against Johnson & Johnson
01:47a JOHNSON & JOHNSON : Janssen receives two u.s. fda approvals for simponi aria® (g..
10/20 JOHNSON & JOHNSON : Ryan Tedder, Hamdi Ulukaya, Bulgari North America Honored at..
10/20 JOHNSON & JOHNSON : blames price cuts in India for poor show in knee-implant bus..
10/20 Healthcare looking in good shape
10/19 JOHNSON & JOHNSON : Janssen Submits New Drug Application to U.S. Food and Drug A..
10/19 JOHNSON & JOHNSON : The Fastest Growing Regions for Dermatological Drug Sales Ar..
10/19 JOHNSON & JOHNSON : Missouri court throws out $72M million verdict in Johnson & ..
10/19 JOHNSON & JOHNSON : Looking back on Black Monday, the stock market crash of 1987
More news
Sector news : Pharmaceuticals - NEC
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19DJEuropean Corporate Roundup for Thursday
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on JOHNSON & JOHNSON 
JOHNSON & JOHNSON - 06/12
The underlying trend is to the upside
BUY
JOHNSON & JOHNSON - 05/10
Expect the comeback of a strong trend
BUY
More Strategies
Qtime:1
News from SeekingAlpha
10/20 FDA OKs expanded uses for J&J's Simponi Aria
10/20 The Best DGI Stocks For Young Investors - October 1-12, 2017
10/20 YOUR DAILY PHARMA SCOOP : Johnson & Johnson's Mixed Signals, Celgene's Mongersen..
10/20 JOHNSON & JOHNSON : Create Your Own Dividends
10/20 I Love Earnings Season! Let's See How Abbott Laboratories, Johnson & Johnson ..
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 144 $
Spread / Average Target 1,1%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372
MERCK AND COMPANY7.88%173 214
AMGEN27.41%135 924